Importantly, increased tumor infiltration of both CD4+ and CD8+ T cells were noted in mice treated with CXCR2 inhibitor and anti-PD-1, indicating that targeting CXCR2 might have the therapeutic potential in the pre-metastatic setting and could also enhance the efficacy of chemotherapy and immunotherapy against pancreatic cancer [47]. This evidence concerns the gene CXCR2 and familial pancreatic carcinoma.